Riffyn, a global provider of Software-as-a-Service (SaaS) for scientific process design and data analytics, announces the close of a $15 million Series B financing led by M Ventures with participation from Waters Corporation, O’Reilly AlphaTech Ventures, and Plug and Play Ventures. Funds will be used to globally expand sales and scientific services, and to accelerate development of Riffyn’s process development and advanced data analytics technology.
● The companies will work together to develop non-invasive Positron Emission Tomography (PET) imaging agents (tracers) targeting CD8, focused on marking cytotoxic T lymphocytes, key predictors of immunotherapy response.
iOnctura SA announced today that its abstract (abstract # 1781) “Preclinical development of a novel, highly selective PI3Kδ inhibitor" has been selected for an oral presentation at the American Association for Cancer Research Annual Meeting 2019.
Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announced the appointment of Professor Rajesh Chopra as Non-Executive Director (NED)
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors